C
Citius Oncology, Inc. (CTOR)
NCM – Real Time Price. Currency in USD
0.90
-0.00 (-0.08%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.90
-0.00 (-0.08%)
At close: May 12, 2026, 4:00 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 0.83 | 2.52 | 5.0 | |
| Quick ratio | 0.32 | 1.78 | 3.0 | |
| Debt to Equity | 0.07 | -0.80 | 9.0 | |
| Debt to Assets | 0.03 | 0.73 | 9.0 | |
| Interest coverage | -114.58 | -13.90 | 1.0 | |
| Weighted average score | 5.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | 4M |
| Gross Profit | N/A | N/A | N/A | N/A | 3M |
| Operating Income | -138K | -1M | -21M | -24M | -22M |
| Net Income | 381K | 2M | -21M | -25M | -24M |
| EBITDA | -138K | -1M | -21M | -24M | -22M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 90.91 | 5.5 |
| Next quarter | N/A | 100 | 5.5 |
| Current year | N/A | 52.94 | 5.5 |
| Next year | 206 | 343.75 | 10 |
| Weighted average score | 6.6 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -10.75 | 0 | -32.89 | 3.3 |
| Y/Y | 999 | 16.9 | 33.33 | N/A | 7.5 |
| 3y average | 999 | -151.97 | N/A | -1826.38 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 3.8 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $7.3M significantly exceed its total debt $3.8M, ensuring strong financial flexibility
Total current liabilities $44.7M surpass Total current assets $37.1M, signaling liquidity issues
Debt-to-equity ratio (0.1) is well below the industry average (-0.8), showcasing prudent financial management
Interest coverage ratio (-114.6x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$7.4M limits the company's ability to reinvest or pay down debt